PG 116800

• UNSPSC Description:

  PG 116800 (PG 530742) is an orally avtive MMP inhibitor. PG 116800 has high affinity for MMP-2, -3, -8, -9, -13, and -14, while having substantially lower affinity for MMP-1 and -7. PG 116800 can be used for knee osteoarthritis research[1].

• Target Antigen:

  MMP

• Type:

  Reference compound

• Related Pathways:

  Metabolic Enzyme/Protease

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/pg-116800.html

• Purity:

  99.81

• Solubility:

  DMSO : 5 mg/mL (ultrasonic;warming;heat to 60°C)

• Smiles:

  OC(C(NS(=O)(C1=CC=C(NC(C2=CC=C(OC)C=C2)=O)C=C1)=O)CC#CCN3CCOCC3)=O

• Molecular Weight:

  501.55

• References & Citations:

  [1]Piotr Krzeski, et al. Development of musculoskeletal toxicity without clear benefit after administration of PG-116800, a matrix metalloproteinase inhibitor, to patients with knee osteoarthritis: a randomized, 12-month, double-blind, placebo-controlled study. Arthritis Res Ther. 2007;9(5):R109.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -20°C, 3 years (Powder)

• Clinical Information:

  Phase 2

• CAS Number:

  291533-11-4